A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

NCT02041260 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Differentiated Thyroid Cancer (DTC)
Poorly Differentiated Thyroid Cancer

Interventions

DRUG: Cabozantinib

Sponsor

Thomas Jefferson University